OCUMENSION-B (01477) announced its interim results for the six months ended June 30, 2025. The company reported revenue of RMB 294 million, representing a 75.4% year-on-year increase. Net loss amounted to RMB 132 million, narrowing by 12.6% compared to the same period last year. Basic loss per share was RMB 0.17.

During the period, several core products maintained stable growth. The company's commercialized products introduced from Alcon progressed smoothly, bringing incremental business and enhancing the product portfolio depth while expanding market opportunities. R&D expenses totaled RMB 39 million, decreasing 33.6% year-on-year, while the research pipeline advanced steadily with multiple products achieving significant progress.

Zhiwei Tai® (0.24% cetirizine eye drops) received NMPA approval for commercialization and is currently the only anti-allergy ophthalmic drug approved by the FDA for patients aged two years and above. OT-703 (ILUVIEN®, fluocinolone acetonide intravitreal implant) was approved by CDE for inclusion in the real-world study pilot program for drugs in Hainan Boao Lecheng International Medical Tourism Pilot Zone, with patient enrollment for real-world studies already commenced.

The group's independently developed product OT-802 (pilocarpine hydrochloride) for presbyopia indication received CDE approval for its Phase III clinical trial application, demonstrating potential to fill the gap in China's current commercialized innovative drug market for presbyopia treatment.

During the reporting period, six of the group's products received production approval. Commercial batch production of the group's products is proceeding in an orderly manner, with the localized production of Yusying® entering the review and public announcement phase.